One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Perspective to 2020 American College of Cardiology/American Heart Association (ACC/AHA) Guideline for the Management of Patients With Valvular Heart Disease
Anthony A. Bavry, George J. Arnaoutakis
doi : 10.1161/CIRCULATIONAHA.120.051501
Circulation. 2021;143:407–409
Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women
Michael C. Honigberg, Seyedeh M. Zekavat, Abhishek Niroula, Gabriel K. Griffin, Alexander G. Bick, James P. Pirruccello, Tetsushi Nakao, Eric A. Whitsel, Leslie V. Farland, Cecelia Laurie, Charles Kooperberg, JoAnn E. Manson, Stacey Gabriel, Peter Libby, Alexander P. Reiner, Benjamin L. Ebert, and NHLBI Trans-Omics for Precision Medicine Program, Pradeep Natarajan
doi : 10.1161/CIRCULATIONAHA.120.051775
Circulation. 2021;143:410–423
Premature menopause is an independent risk factor for cardiovascular disease in women, but mechanisms underlying this association remain unclear. Clonal hematopoiesis of indeterminate potential (CHIP), the age-related expansion of hematopoietic cells with leukemogenic mutations without detectable malignancy, is associated with accelerated atherosclerosis. Whether premature menopause is associated with CHIP is unknown.
Clonal Hematopoiesis and Premature Menopause
Silvia Mas-Peiro, Sebastian Cremer, Andreas M Zeiher
doi : 10.1161/CIRCULATIONAHA.120.052293
Circulation. 2021;143:424–426
An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure With Reduced Ejection Fraction
Larry A. Allen, Grace Venechuk, Colleen K. McIlvennan, Robert L. Page II, Christopher E. Knoepke, Laura J. Helmkamp, Prateeti Khazanie, Pamela N. Peterson, Kenneth Pierce, Geoffrey Harger, Jocelyn S. Thompson, Tristan J. Dow, Lance Richards, Janice Huang, James R. Strader, Katy E. Trinkley, David P. Kao, David J. Magid, Peter M. Buttrick, Daniel D. Matlock
doi : 10.1161/CIRCULATIONAHA.120.051863
Circulation. 2021;143:427–437
Major gaps exist in the routine initiation and dose up-titration of guideline-directed medical therapies (GDMT) for patients with heart failure with reduced ejection fraction. Without novel approaches to improve prescribing, the cumulative benefits of heart failure with reduced ejection fraction treatment will be largely unrealized. Direct-to-consumer marketing and shared decision making reflect a culture where patients are increasingly involved in treatment choices, creating opportunities for prescribing interventions that engage patients.
Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
John J.V. McMurray, David C. Wheeler, Bergur V. Stef?nsson, Niels Jongs, Douwe Postmus, Ricardo Correa-Rotter, Glenn M. Chertow, Tom Greene, Claes Held, Fan-Fan Hou, Johannes F.E. Mann, Peter Rossing, C. David Sj?str?m, Roberto D. Toto, Anna Maria Langkilde, Hiddo J.L. Heerspink, and For the DAPA-CKD Trial Committees and Investigators
doi : 10.1161/CIRCULATIONAHA.120.051675
Circulation. 2021;143:438–448
Dapagliflozin reduces the risk of end-stage renal disease in patients with chronic kidney disease. We examined the relative risk of cardiovascular and renal events in these patients and the effect of dapagliflozin on either type of event, taking account of history of cardiovascular disease.
Oxidation of Protein Kinase A Regulatory Subunit PKARI? Protects Against Myocardial Ischemia-Reperfusion Injury by Inhibiting Lysosomal-Triggered Calcium Release
Jillian N. Simon, Besarte Vrellaku, Stefania Monterisi, Sandy M. Chu, Nadiia Rawlings, Oliver Lomas, Gerard A. Marchal, Dominic Waithe, Fahima Syeda, Parag R. Gajendragadkar, Raja Jayaram, Rana Sayeed, Keith M. Channon, Larissa Fabritz, Pawel Swietach, Manuela Zaccolo, Philip Eaton, Barbara Casadei
doi : 10.1161/CIRCULATIONAHA.120.046761
Circulation. 2021;143:449–465
Kinase oxidation is a critical signaling mechanism through which changes in the intracellular redox state alter cardiac function. In the myocardium, PKARI? (type-1 protein kinase A) can be reversibly oxidized, forming interprotein disulfide bonds in the holoenzyme complex. However, the effect of PKARI? disulfide formation on downstream signaling in the heart, particularly under states of oxidative stress such as ischemia and reperfusion (I/R), remains unexplored.
What You Did Not Know About Cardiac Ca2+ Handling
Kirsten T. Nijholt, Rudolf A. de Boer, B. Daan Westenbrink
doi : 10.1161/CIRCULATIONAHA.120.052677
Circulation. 2021;143:466–469
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease
Nicholas A. Marston, Parth N. Patel, Frederick K. Kamanu, Francesco Nordio, Giorgio M. Melloni, Carolina Roselli, Yared Gurmu, Lu-Chen Weng, Marc P. Bonaca, Robert P. Giugliano, Benjamin M. Scirica, Michelle L. O’Donoghue, Christopher P. Cannon, Christopher D. Anderson, Deepak L. Bhatt, Philippe Gabriel Steg, Marc Cohen, Robert F. Storey, Peter Sever, Anthony C. Keech, Itamar Raz, Ofri Mosenzon, Elliott M. Antman, Eugene Braunwald, Patrick T. Ellinor, Steven A. Lubitz, Marc S. Sabatine, Christian T. Ruff See fewer authors
doi : 10.1161/CIRCULATIONAHA.120.051927
Circulation. 2021;143:470–478
Genome-wide association studies have identified single-nucleotide polymorphisms that are associated with an increased risk of stroke. We sought to determine whether a genetic risk score (GRS) could identify subjects at higher risk for ischemic stroke after accounting for traditional clinical risk factors in 5 trials across the spectrum of cardiometabolic disease.
Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations
Luiz F. Ybarra, Stéphane Rinfret, Emmanouil S. Brilakis, Dimitri Karmpaliotis, Lorenzo Azzalini, J. Aaron Grantham, David E. Kandzari, Kambis Mashayekhi, James C. Spratt, Harindra C. Wijeysundera, Ziad A. Ali, Christopher E. Buller, Mauro Carlino, David J. Cohen, Donald E. Cutlip, Tony De Martini, Carlo Di Mario, Andrew Farb, Aloke V. Finn, Alfredo R. Galassi, C. Michael Gibson, Colm Hanratty, Jonathan M. Hill, Farouc A. Jaffer, Mitchell W. Krucoff, William L. Lombardi, Akiko Maehara, P.F. Adrian Magee, Roxana Mehran, Jeffrey W. Moses, William J. Nicholson, Yoshinobu Onuma, Georgios Sianos, Satoru Sumitsuji, Etsuo Tsuchikane, Renu Virmani, Simon J. Walsh, Gerald S. Werner, Masahisa Yamane, Gregg W. Stone, Stéphane Rinfret, Gregg W. Stone, and On behalf of the Chronic Total Occlusion Academic Research Consortium See fewer authors
doi : 10.1161/CIRCULATIONAHA.120.046754
Circulation. 2021;143:479–500
Over the past 2 decades, chronic total occlusion (CTO) percutaneous coronary intervention has developed into its own subspecialty of interventional cardiology. Dedicated terminology, techniques, devices, courses, and training programs have enabled progressive advancements. However, only a few randomized trials have been performed to evaluate the safety and efficacy of CTO percutaneous coronary intervention. Moreover, several published observational studies have shown conflicting data. Part of the paucity of clinical data stems from the fact that prior studies have been suboptimally designed and performed. The absence of standardized end points and the discrepancy in definitions also prevent consistency and uniform interpretability of reported results in CTO intervention. To standardize the field, we therefore assembled a broad consortium comprising academicians, practicing physicians, researchers, medical society representatives, and regulators (US Food and Drug Administration) to develop methods, end points, biomarkers, parameters, data, materials, processes, procedures, evaluations, tools, and techniques for CTO interventions. This article summarizes the effort and is organized into 3 sections: key elements and procedural definitions, end point definitions, and clinical trial design principles. The Chronic Total Occlusion Academic Research Consortium is a first step toward improved comparability and interpretability of study results, supplying an increasingly growing body of CTO percutaneous coronary intervention evidence.
AHA Takes Aim at Structural Racism as a Public Health Crisis
Bridget M. Kuehn
doi : 10.1161/CIRCULATIONAHA.120.053306
Circulation. 2021;143:501–502
Narrowing the Differential Diagnosis for a Wide Complex Tachycardia
Andrew Y. Chen, Takuro Nishimura, Roderick Tung
doi : 10.1161/CIRCULATIONAHA.120.052373
Circulation. 2021;143:503–506
Digital Care Transformation
Benjamin M. Scirica, Christopher P. Cannon, Naomi D.L. Fisher, Thomas A. Gaziano, David Zelle, Kira Chaney, Angela Miller, Hunter Nichols, Lina Matta, William J. Gordon, Shawn Murphy, Kavi B. Wagholikar, Jorge Plutzky, Calum A. MacRae
doi : 10.1161/CIRCULATIONAHA.120.051913
Circulation. 2021;143:507–509
Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus
Chi Young Shim, Jiwon Seo, Iksung Cho, Chan Joo Lee, In-Jeong Cho, Purevjargal Lhagvasuren, Seok-Min Kang, Jong-Won Ha, Gyoonhee Han, Yangsoo Jang, Geu-Ru Hong
doi : 10.1161/CIRCULATIONAHA.120.051992
Circulation. 2021;143:510–512
Letter by Albiero and Seresini Regarding Article, “Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan, China: Prevalence, Risk Factors, and Outcome”
Remo Albiero, Giuseppe Seresini
doi : 10.1161/CIRCULATIONAHA.120.050551
Circulation. 2021;143:e31–e32
Response by Zhang et al to Letter Regarding Article, “Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan, China: Prevalence, Risk Factors, and Outcome”
Remo Albiero, Giuseppe Seresini
doi : 10.1161/CIRCULATIONAHA.120.051629
Circulation. 2021;143:e33–e34
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Catherine M. Otto, Rick A. Nishimura, Robert O. Bonow, Blase A. Carabello, John P. Erwin III, Federico Gentile, Hani Jneid, Eric V. Krieger, Michael Mack, Christopher McLeod, Patrick T. O’Gara, Vera H. Rigolin, Thoralf M. Sundt III, Annemarie Thompson, Christopher Toly
doi : 10.1161/CIR.0000000000000932
Circulation. 2021;143:e35–e71
This executive summary of the valvular heart disease guideline provides recommendations for clinicians to diagnose and manage valvular heart disease as well as supporting documentation to encourage their use.
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Catherine M. Otto, Rick A. Nishimura, Robert O. Bonow, Blase A. Carabello, John P. Erwin III, Federico Gentile, Hani Jneid, Eric V. Krieger, Michael Mack, Christopher McLeod, Patrick T. O’Gara, Vera H. Rigolin, Thoralf M. Sundt III, Annemarie Thompson, Christopher Toly
doi : 10.1161/CIR.0000000000000923
Circulation. 2021;143:e72–e227
Correction to: 2020 ACC/AHA Guideline on the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
doi : 10.1161/CIR.0000000000000960
Circulation. 2021;143:e228
Correction to: 2020 ACC/AHA Guideline on the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
doi : 10.1161/CIR.0000000000000955
Circulation. 2021;143:e229
